Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT05116046
Other study ID # C4181008
Secondary ID 2021-003149-39
Status Terminated
Phase Phase 2
First received
Last updated
Start date December 24, 2021
Est. completion date March 30, 2023

Study information

Verified date February 2024
Source Pfizer
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

All participants who completed the prior study to assess long-term safety, tolerability, pharmacokinetics and efficacy, and in the opinion of the investigator, continue to have a positive risk:benefit profile, will be offered to enroll in this open-label extension (OLE) study for up to an additional 24 months of treatment. Approximately 63 participants will be offered to continue at the previously received dose of Recifercept either Low Dose Medium Dose High Dose or at the therapeutic dose once it is identified. Participants will attend the clinic monthly for 24 months. Assessments include safety, blood sampling, physical examination, vital signs, anthropometric body measurements & patient/caregiver quality of life questionnaires.


Recruitment information / eligibility

Status Terminated
Enrollment 35
Est. completion date March 30, 2023
Est. primary completion date December 16, 2022
Accepts healthy volunteers No
Gender All
Age group 15 Months to 12 Years
Eligibility Inclusion Criteria: - Male and female participants between the ages of >15 months to <12 years inclusive, at Visit 1 (Screen 1). - Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests lifestyle considerations and other study procedures. - Completed the C4181005 Phase 2 study. - Able to stand independently for height measurements (if =2 years of age at enrollment). Exclusion Criteria: - Presence of co-morbid conditions or circumstances that, in the opinion of the investigator, would affect interpretation of growth data or ability to complete the trial procedures. - Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study. - Presence of severe obesity (body mass index (BMI) >95th percentile on Hoover-Fong BMI charts) [Hoover-Fong et al, 2008]. - Known closure of long bone growth plates (cessation of height growth). - Body weight >45 kg. - History of hypersensitivity to study intervention or any excipients. - History of any prior treatment with human growth hormone or related products (including insulin-like growth factor 1 [IGF-1]). - History of receipt of any treatment that are known to potentially affect growth (including oral steroids >5 days in the last 6 months, high dose inhaled corticosteroids (>800 mcg/day beclometasone equivalent) and medication for attention deficit hyperactivity disorder). - History of limb lengthening surgery (defined as distraction osteogenesis/Ilizarov/callostasis technique following submetaphyseal osteotomy to extend bone length). - Any limb lengthening/corrective orthopaedic surgery planned at any point during the trial period. - Less than 6 months since fracture or surgical procedure of any bone determined from the screening visit date. - Presence of any internal guided growth plates/devices. - History of removal of internal guided growth plates/devices within less than 6 months. - History of receipt of any other (except recifercept) investigational product for achondroplasia or that may affect growth/interpretation of growth parameters. - History of receipt of an investigational drug (not for achondroplasia/growth affecting) within the last 30 days (or as determined by the local requirement) or 5 half-lives preceding the first dose of study intervention used in this study (whichever is longer).

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Recifercept
Recifercept

Locations

Country Name City State
Australia Murdoch Children's Research Institute Parkville Victoria
Belgium Antwerp University Hospital Edegem
Belgium UZ Leuven - Center of Human Genetics Leuven Vlaams - Gewest
Denmark Bispebjerg Hospital Copenhagen
Denmark Bispebjerg Hospital Kobenhavn
Italy Fondazione Policlinico Universitario Agostino Gemelli IRCCS Università Cattolica del Sacro Cuore Roma
Portugal Centro Hospitalar e Universitário de Coimbra - Hospital Pediátrico Coimbra
Spain Hospital Vithas San Jose Vitoria - Gasteiz Alava
United States Texas Childrens Hospital/Baylor College of Medicine Houston Texas
United States Ocean Sleep Medicine Irvine California
United States Long Beach Memorial Medical Center Long Beach California
United States MemorialCare Sleep Disorders Center at Long Beach Memorial Medical Center Long Beach California
United States Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center Torrance California
United States Nemours Children's Hospital, Delaware Wilmington Delaware

Sponsors (1)

Lead Sponsor Collaborator
Pfizer

Countries where clinical trial is conducted

United States,  Australia,  Belgium,  Denmark,  Italy,  Portugal,  Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Severe AEs An AE was any untoward medical occurrence that did not necessarily have a causal relationship with study treatment. TEAE was an AE that occurred after initiation of study treatment that was not present at the time of treatment start or an AE that increased in severity after the initiation of medication, if the event was present at the time of treatment start emerges. SAE was an AE resulting in any of the following outcomes or considered medically significant: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly or birth defect. Severe AEs were AEs that were medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated disabling, limiting self-care activities of daily living. From first dose of study drug up to 28 days after last dose of study drug (maximum up to 11 months)
Primary Change From Baseline in Height at Month 24 Height was measured using anthropometric measurements. Anthropometric data was collected by appropriately trained individuals at the trial site and in accordance with the anthropometric measurement manual. Baseline, Month 24
Secondary Clearance (CL/F) of Recifercept Clearance of a drug was a measure of the rate at which a drug is metabolised or eliminated by normal biological processes. Predose on Day 91, 181, 271, 361 and 451.
Secondary Change From Baseline in Sitting Height to Standing Height Ratio at Months 3, 6, 9 Sitting height to standing height ratio was calculated based upon the anthropometric measurements. Anthropometric data was collected by appropriately trained individuals at the trial site and in accordance with the anthropometric measurement manual. Baseline and Months 3, 6, 9
Secondary Change From Baseline in Arm Span to Height/Length Difference at Months 3, 6, 9 Height and length difference was calculated with anthropometric measurements. Anthropometric data was collected by appropriately trained individuals at the trial site and in accordance with the anthropometric measurement manual. Baseline and Months 3, 6, 9
Secondary Change From Baseline in Knee Height to Lower Segment Ratio at Months 3, 6, 9 Knee height was defined as the distance from the sole of the foot to the most anterior surface of the femoral condyles of the thigh (medial being more anterior), with the ankle and knee each flexed to a 90-degree angle. Lower segment of the leg included tibia and foot height Baseline and Months 3, 6, 9
Secondary Change From Baseline in Occipito-Frontal Circumference at Months 3, 6, 9 Occipito-frontal circumference was measured by anthropometric measurements. It was measured over the most prominent part on the back of the head (occiput) and just above the eyebrows (supraorbital ridges). Baseline and Months 3, 6, 9
Secondary Change From Baseline in Occipito-Frontal Distance to Occipito-mid-Face Measurements Ratio at Months 3, 6, 9 Occipito-frontal circumference was measured by anthropometric measurements. Anthropometric data was collected by appropriately trained individuals at the trial site and in accordance with the anthropometric measurement manual. Baseline, Months 3, 6, 9
Secondary Change From Baseline in Z-Score for Occipito-frontal Circumference, Arm Span, Sitting Height and Skull Morphology at Months 3, 6, 9 The Z-score described how many standard deviations a given measurement lies above or below a size or age-specific population mean. A Z-score above the population mean indicates a positive value, whereas a Z-score below the population mean indicates a negative value. The greater the deviation of the Z-score from zero (in a positive or negative direction), the greater the magnitude of deviation from the mean. Baseline, Months 3, 6, 9
Secondary Change From Baseline in Fixed Flexion Angles at Elbow at Months 3, 6, 9 Fixed Flexion Angles was measured by anthropometric measurements. Anthropometric data was collected by appropriately trained individuals at the trial site and in accordance with the anthropometric measurement manual. Baseline, Months 3, 6, 9
Secondary Change From Baseline in Body Mass Index (BMI) at Months 3, 6, 9 Baseline, Months 3, 6, 9
Secondary Change From Baseline in Waist to Chest Circumference Ratio at Months 3, 6, 9 Baseline, Months 3, 6, 9
Secondary Number of Participants With Clinically Meaningful Findings in Laboratory Test Parameters Through the Study Laboratory parameters that were assessed included lymphocytes, neutrophils, eosinophils, monocytes and potassium. Clinically significant abnormal laboratory findings were determined based on investigator's decision. From baseline up to end of study/early termination (for a maximum duration of 11 months)
Secondary Number of Participants With Clinically Significant Findings in Vital Signs Through the Study Absolute values and changes from baseline in supine systolic and diastolic blood pressure, oral temperature, and pulse rate were planned to be summarized by treatment in accordance with the sponsor reporting standards. Clinically significant abnormal laboratory findings were those which were not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. From baseline up to end of study/early termination (for a maximum duration of 11 months)
Secondary Number of Participants With Clinically Significant Findings in Physical Examination Through the Study A complete physical examination included cardiovascular, respiratory, gastrointestinal systems, and skin. Height and weight will also be measured and recorded as part of the anthropometric measurements collected. Anthropometric data was collected by appropriately trained individuals at the trial site and in accordance with the anthropometric measurement manual. From baseline up to end of study/early termination (for a maximum duration of 11 months)
Secondary Number of Participants With Positive Anti-Drug Antibodies (ADA) From Month 3 up to end of study/early termination (up to Month 11)
See also
  Status Clinical Trial Phase
Recruiting NCT05353192 - A Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone in Children With Achondroplasia Phase 4
Recruiting NCT05328050 - Registry for Patients With Achondroplasia / Hypochondroplasia (OMPR-Ach/Hy)
Completed NCT05659719 - A Study to Learn About Recifercept in Patients With Achondroplasia
Active, not recruiting NCT04554940 - A Clinical Trial to Evaluate Safety of Vosoritide in At-risk Infants With Achondroplasia Phase 2
Completed NCT01435629 - A Survey Collecting Data on Adult Height in Patients With Achondroplasia Treated With Somatropin N/A
Enrolling by invitation NCT06164951 - A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia Phase 3
Completed NCT03583697 - A Clinical Trial to Evaluate the Safety and Efficacy of BMN 111 in Infants and Young Children With Achondroplasia Phase 2
Completed NCT01516229 - Special Survey for Long Term Application N/A
Completed NCT03872531 - Lifetime Impact Study for Achondroplasia
Active, not recruiting NCT05598320 - A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Children With Achondroplasia Phase 2/Phase 3
Terminated NCT05813314 - Bioequivalence Study to Compare Two Injection Devices for BMN 111 in Healthy Participants Phase 1
Recruiting NCT04265651 - Study of Infigratinib in Children With Achondroplasia Phase 2
Recruiting NCT05603936 - Adaption and Testing of the Quality of Life in Short Stature Youth (QoLISSY) Questionnaire for Parents With Children From 0-4
Completed NCT03780153 - The Norwegian Adult Achondroplasia Study
Active, not recruiting NCT04085523 - A Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of TransCon CNP Administered Once Weekly in Prepubertal Children With Achondroplasia Phase 2
Enrolling by invitation NCT05929807 - A Clinical Trial to Investigate Long-term Safety, Tolerability, and Efficacy of Weekly Subcutaneous Doses With TransCon CNP in Children and Adolescents With Achondroplasia Phase 2/Phase 3
Completed NCT03875534 - A Multi-center, Longitudinal, Observational Study of Children With Achondroplasia
Terminated NCT03794609 - Observational Study Investigating Clinical & Anthropometric Characteristics of Children With Achondroplasia.
Active, not recruiting NCT03989947 - An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With Achondroplasia Phase 2
Active, not recruiting NCT05246033 - A Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of Multiple Subcutaneous Doses of TransCon CNP Administered Once Weekly in Children With Achondroplasia Phase 2